A clinical trial to study the effects of additional treatments for patients hospitalized and receiving treatment due to COVID -19.
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2020/04/024773
- Lead Sponsor
- World Health Organization
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Suspended
- Sex
- Not specified
- Target Recruitment
- 0
1. Adults (age >=18 years) recently hospitalised, or already in the hospital, with definite (diagnosed by RT-PCR) symptomatic COVID admitted for at least moderate or severe illness
2. In the view of the responsible doctor, no contra-indication to any of the study drugs.
3. Providing consent for the participation
1.Adults (age >=18 years) with COVID and hospitalised for quarantine purposes or management of other conditions who do not have moderate or severe illness.
2.Laboratory confirmation of SARS Cov -2 infection not available
3.In the view of the randomising doctor, ANY of the AVAILABLE study drugs are contra-indicated
Anticipated transfer to another hospital which is not a study site within 72 hours
4.Pregnant or Lactating Women
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method All-cause mortality, subdivided by the severity of disease at the time of randomization, measured using patient records throughout the studyTimepoint: Throughout the study
- Secondary Outcome Measures
Name Time Method Measured using patient records: <br/ ><br>1. Duration of hospital stay (hours) <br/ ><br>2. Time to first receiving ventilation (or intensive care) (hours)Timepoint: Measured using patient records: <br/ ><br>1. Duration of hospital stay (hours) <br/ ><br>2. Time to first receiving ventilation (or intensive care) (hours)